|Day Low/High||259.20 / 261.84|
|52 Wk Low/High||98.02 / 230.77|
Why aren't we figuring out how to cure the test bottleneck?
These names are showing both technical and quantitative deterioration.
Look for weaknesses in companies like these that can provide solutions to today's pressing issues.
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
These 'Bearish Bets' are showing both technical and quantitative deterioration.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...
LH's $5.7B Covance takeover could be just what the doctor ordered.
Most of the Lab Corp. of America's key metrics approximately tripled from 2005 through 2015.
This entry is in response to a question posed by FreakGuy666. It all hinges on what you mean by "under the radar?" I take it to mean those diamonds in the rough that lack Wall Street research coverage or fall below the $5 price threshold. One that f...
We saw this coming, but there's more to the recent turmoil than China.
Conditions still appear grim, but these picks should be able to weather the storm.
Selling covered calls and naked puts can reduce risk. (Updated)
Try this options play for the sometimes volatile Bio-Reference Laboratories.
Quest Diagnostics -- and others in this beaten-down sector -- are excellent trading vehicles.